Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Carroll

Showing results (531-540 of 573) with videos related to

Pageof 58
Sort By:
Nature Structural & Molecular Biology|October 16, 2020
Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2Jiangdong Huo, Audrey Le Bas, Reinis R Ruza, et al.
Journal of the Canadian Association of Gastroenterology|November 10, 2021
Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive SummaryM Ellen Kuenzig, Joseph W Windsor, Lisa Barrett, et al.
Nature Structural & Molecular Biology|July 15, 2020
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2Jiandong Huo, Audrey Le Bas, Reinis R Ruza, et al.
Nature Structural & Molecular Biology|February 4, 2021
Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2Jiandong Huo, Audrey Le Bas, Reinis R Ruza, et al.
BMC Medicine|November 7, 2024
rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l'essai proches)Conall H Watson, Pierre-Stéphane Gsell, Yper Hall, et al.
Eclinicalmedicine|January 4, 2021
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trialPablo Tebas, ShuPing Yang, Jean D Boyer, et al.
The Lancet. Global Health|December 14, 2016
Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling studyDaouda Sissoko, Sophie Duraffour, Romy Kerber, et al.
Iscience|December 13, 2023
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescentsHelen Ratcliffe, Karen S Tiley, Stephanie Longet, et al.
The Lancet. Infectious Diseases|October 16, 2020
Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort studyRuth Thom, Thomas Tipton, Thomas Strecker, et al.
Plos Neglected Tropical Diseases|May 31, 2017
Different features of Vδ2 T and NK cells in fatal and non-fatal human Ebola infectionsEleonora Cimini, Domenico Viola, Mar Cabeza-Cabrerizo, et al.
Pageof 58

Showing results (531-540 of 573) with videos related to

Sort By:
Pageof 58
Nature Structural & Molecular Biology|October 16, 2020
Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2Jiangdong Huo, Audrey Le Bas, Reinis R Ruza, et al.
Journal of the Canadian Association of Gastroenterology|November 10, 2021
Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive SummaryM Ellen Kuenzig, Joseph W Windsor, Lisa Barrett, et al.
Nature Structural & Molecular Biology|July 15, 2020
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2Jiandong Huo, Audrey Le Bas, Reinis R Ruza, et al.
Nature Structural & Molecular Biology|February 4, 2021
Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2Jiandong Huo, Audrey Le Bas, Reinis R Ruza, et al.
BMC Medicine|November 7, 2024
rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l'essai proches)Conall H Watson, Pierre-Stéphane Gsell, Yper Hall, et al.
Eclinicalmedicine|January 4, 2021
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trialPablo Tebas, ShuPing Yang, Jean D Boyer, et al.
The Lancet. Global Health|December 14, 2016
Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling studyDaouda Sissoko, Sophie Duraffour, Romy Kerber, et al.
Iscience|December 13, 2023
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescentsHelen Ratcliffe, Karen S Tiley, Stephanie Longet, et al.
The Lancet. Infectious Diseases|October 16, 2020
Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort studyRuth Thom, Thomas Tipton, Thomas Strecker, et al.
Plos Neglected Tropical Diseases|May 31, 2017
Different features of Vδ2 T and NK cells in fatal and non-fatal human Ebola infectionsEleonora Cimini, Domenico Viola, Mar Cabeza-Cabrerizo, et al.
Pageof 58